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Background-—In vitro study showed that NADPH oxidase (NOx), the most important enzyme producing reactive oxygen species
(ROS), plays a role in the process of platelet activation. However, it is unclear if changes in its activity affect platelet activation
in vivo.
Methods and Results-—In vivo and ex vivo experiments assessing platelet activation were investigated in healthy subjects, obese
patients, and subjects with different low rates of NOx2 activity, namely X-linked chronic granulomatous disease (X-CGD) patients
and X-CGD carriers. We included 27 X-CGD patients, 31 women carriers of hereditary deﬁciency of NOx2, 31 obese women, and 62
healthy subjects matched for sex and age. Plasma levels of soluble sCD40 L (sCD40L) and soluble P (sP)-selectin, 2 markers of in
vivo platelet activation, were reduced in X-CGD patients (sCD40L=55%; sP-selectin=51%, P<0.001) and in X-CGD carriers
(sCD40L=41%; sP-selectin=57%, P<0.001) compared with respective controls. Conversely, obese women, who disclosed NOx2
upregulation, had signiﬁcantly higher plasma levels of sCD40L (+47%, P<0.001) and sP-selectin (+70%, P<0.001) compared with
controls. Ex vivo study showed platelet isoprostane downexpression and enhanced platelet NO generation in both X-CGD patients
and X-CGD carriers compared with controls; opposite ﬁndings were observed in obese patients. Correlation analysis showed that
platelet NOx2 regulation was directly associated with plasma levels of sCD40L (R=0.336, P<0.001) and sP-selectin (R=0.441;
P<0.001).
Conclusions-—The study provides the ﬁrst evidence that in vivo platelet activation is signiﬁcantly and directly associated with
NOx2 activity. Platelet NOx2 may be a novel target for platelet activation inhibition. ( J Am Heart Assoc. 2014;3:e000920 doi:
10.1161/JAHA.114.000920)
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R eactive oxygen species (ROS) are chemically unstablemolecules that rapidly react with other molecules,
inducing the formation of oxidized products such as oxidized
low-density lipoprotein, peroxynitrite, or protein adducts.1,2
ROS serve as second messengers at physiologic concentration
and, as such, they behave as intracellular signals for cell
activation.1 Among the cells, platelets represent a typical
example of ROS involvement in the activation process.3 Thus,
on stimulation by common agonists, platelets produce several
types of ROS such as superoxide anion (O2
) or hydrogen
peroxide (H2O2), which in turn contribute to the propagation of
platelet aggregation.4 There are several enzymatic pathways
that elicit the formation of ROS into the cells, including NADPH
oxidase (NOx), myeloperoxidase, xanthine oxidase, and uncou-
pled nitric oxide synthase. Amid these, experimental and
clinical evidence focused on the role of NOx as the key enzyme
in producing ROS and eventually eliciting platelet activation.5–7
In particular, Krotz et al 8,9 demonstrated that NOx-dependent
platelet O2
 formation enhances platelet aggregation and
platelet-dependent thrombosis. In accordance with this ﬁnding,
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we observed that in subjects with hereditary deﬁciency of
NOx2, the catalytic subunit of NOx, an impaired O2
 formation
occurred. Also, agonist-induced platelet aggregation was
reduced, which further supports the role of O2
 in eliciting
platelet activation.6 It is unclear, however, if an interplay
between NOx2 activity and platelet activation does exist in vivo.
To explore this issue, we examined markers of in vivo platelet
activation, such as soluble CD40L (sCD40L) and soluble
P-selectin (sP-s), in subjects with different degrees of NOx2
activity including youths with X-linked chronic granulomatous
disease (X-CGD), adult carriers of NOx2 hereditary deﬁciency,
healthy subjects (HS), and obese subjects, who are known to
disclose NOx2 upregulation.10–12
Methods
Study Population
We conducted a multicentre study in collaboration with the
Italian Primary Immunodeﬁciency Network. Among the 60
patients with CGD registered in the national database,13 28
were not included in the study due to the presence of acute
infections or critical physical conditions or unwillingness to
participate in the study; 5 patients with p47phox hereditary
deﬁciency were excluded. The remaining 27, who were X-CGD
patients were included; 31 age-matched HS were also
included. Furthermore, among the female relatives of the 60
CGD patients registered in the national database,13 we studied
31 female carriers of X-CGD who were willing to participate in
the study. The group of carriers was composed of 23 mothers,
3 grandmothers, and 5 sisters of X-CGD patients.
Diagnosis of X-CGD was performed as previously
described.13 All X-CGD patients were under treatment with
itraconazole, trimethoprim, and sulfamethoxazole.
Thirty-one women matched for age and atherosclerotic risk
factors were screened from routine visits and used as controls.
Further, we included 31 age-matched obese female subjects;
body mass index (BMI) ≥30 kg/m2 was used as a cut-off to
deﬁne obesity. In 2 female subjects, aged 9 and 10 years,
obesity was deﬁned as a BMI ≥95th percentile.14 Controls and
obese patients were recruited from the outpatient clinic of our
division at the “I Clinica Medica” of the Sapienza University of
Rome. None of the patients included in the study had a clinical
history complicated by thrombotic events and were taking
antiplatelet drugs during the month before blood sampling.
HS matched for sex, age, and atherosclerotic risk factors
were screened from routine visits. Subjects were excluded
from the study if they had liver insufﬁciency, serious renal
disorders (serum creatinine >2.8 mg/dL), cancer, myocardial
infarction, unstable angina, acute cerebrovascular disease,
deep venous thrombosis; were in treatment with statins or
antioxidant vitamins; or were a current smoker.
The study was approved by the Ethical Committee of
Sapienza University. Each subject enrolled gave informed
consent to participate in the study.
Blood Sampling
After overnight fasting (12 hours) and supine rest for at least
10 minutes, blood samples were collected in vacutainers
between 8 and 9 AM (Vacutainer Systems, Belliver Industrial
Estate) and centrifuged at 300g for 10 minutes to obtain
supernatant, which was stored at 80°C until use.
Total cholesterol was measured according to routine
methods using an enzymatic colorimetric method on a
Dimension RXL apparatus (Dade Behring AG).
Platelet Preparation
To obtain platelet-rich plasma, blood samples mixed with 3.8%
NA citrate (ratio 9:1) were centrifuged for 15 minutes at 180g.
To avoid leukocyte contamination, only the top 75% of the
platelet-rich plasmawas collected according to Pignatelli et al.6
Platelet pellets were obtained via centrifugation (10 min-
utes, 300g) of platelet-rich plasma. Acid citrate–dextrose (1:7
v/v) was added to avoid platelet activation during processing;
samples were suspended in HEPES buffer in presence of 0.1%
albumin, pH 7.35 (29108/mL). Supernatant was separated
from cells and stored until analysis.
Platelet 8-Iso-Prostaglandin F2a Assays
Concentration of 8-iso-prostaglandin (PG)F2a in supernatant
of platelet was measured by using a previously described and
validated enzyme immunoassay method (Tema Ricerca)15,16
and expressed as pmol/L. Intra-assay and interassay coefﬁ-
cients of variation were 4.4% and 8.8% respectively.
Platelet Soluble NOx2-Derived Peptide
Platelet soluble NOx2-derived peptide (sNOx2-dp), a marker of
NADPH oxidase activation, was detected in platelets super-
natant by using the ELISA method as previously described by
Pignatelli et al.17 The peptide was recognized by the speciﬁc
monoclonal antibody against the amino acidic sequence (224
to 268) of the extramembrane portion of NOx2. Values were
expressed as pg/mL, and intra-assay and interassay coefﬁ-
cients of variation were 5.2% and 6%, respectively, for serum
and platelets.
Platelets NOx Measurement
A colorimetric assay kit (Tema Ricerca, Italy) was used to
determine the nitric oxide metabolites nitrite and nitrate
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(NOx) in the supernatant of platelet. Intra-assay and interas-
say coefﬁcients of variation were 2.9% and 1.7%, respectively.
Plasma and Platelet Levels of sCD40L and sP-
selectin
Plasma and platelet levels of sCD40L and sP-selectin were
measured with use of a commercial immunoassay (Tema
Ricerca). Intra-assay and interassay coefﬁcients of variation
were 5% and 7% for sCD40L and 4.3% and 6.1% for sP-
selectin, respectively.
Statistical Analysis
Data are presented as meanSD unless indicated otherwise.
Categorical variables were reported as counts (percentage);
independence of categorical variables was tested by using v2
test. The correlation analysis was carried out via Pearson
correlation test. We performed an ANOVA to compare means
across the groups; post-hoc analysis was performed with
Tukey’s test. Results were further conﬁrmed by nonparamet-
ric tests (Mann–Whitney for pairwise comparisons and
Kruskal–Wallis test for all groups in 1 analysis). Statistical
signiﬁcance was deﬁned at P<0.05. Statistical analysis was
performed with SPSS 18.0 for Windows (SPSS Inc).
For sample size determination, on the basis of the data
emerging from previous studies,10,11 we computed the
minimum sample size with respect to a 2-sample Student t
test, considering (1) relevant difference for plasma CD40L
variation to be detected between the X-CGD patients and
controls; (2) standard deviations to be homogeneous between
groups 16; and (3) type I error probability a=0.05 and power
1b=0.90. This resulted in a minimum sample size of 19
subjects for each group. Sample size calculations was
performed using the software nQuery Advisor, version 5.0
(Statistical Solutions, Saugus, MA).
Results
Clinical characteristics of the 5 groups, which include X-CGD
patients, X-CGD carriers, children and adult controls, and
obese subjects (n=151), were reported in Tables 1 and 2. No
signiﬁcant difference in medications was detected among the
groups (Table 2).
There were no differences in terms of age, sex, and risk
factors of atherosclerosis between X-CGD, X-CGD carriers,
and the respective controls (Tables 1 and 2). As expected,
BMI was signiﬁcantly higher in obese subjects compared with
the other groups (Table 2).
Compared with young HS, plasma levels of sCD40L and sP-
selectin were reduced in X-CGD patients (55%, P<0.001,
and 51%, P<0.001, respectively) (Table 1 and Figure 1).
Compared with adults controls, X-CGD carriers had lower
plasma levels of sCD40L and sP-selectin (46% and 57%,
respectively, P<0.001) (Table 2 and Figure 1). Also, compared
with controls, obese women had higher plasma levels of
sCD40L and sP-selectin (+47% and +70%, respectively,
P<0.001) (Table 2 and Figure 1).
A correlation analysis in the overall population showed
that platelet sNOx2-dp correlated with platelet 8-iso-PGF2a
(r=0.584, P<0.001), platelet NOx (r=0.320, P<0.001),
plasma sP-selectin (r=0.336, P<0.001), sCD40L (r=0.441,
P<0.001), total cholesterol (r=0.275, P=0.001), age (r=0.176,
Table 1. Clinical Characteristics of X-Chronic Granulomatous Disease (X-CGD) Patients and Controls
X-CGD (n=27) Controls (n=31) P Value
Age, y 16.39.2 16.68.4 1.0
Gender 27 males 31 males n.s.
Systolic blood pressure, mm Hg 11011 1088 1.0
Diastolic blood pressure, mm Hg 688 708 1.0
BMI 18.32.9 19.82.9 1.0
Total-cholesterol, mg/dL 128.820.7 138.015.6 1.0
Plasma sP-selectin, ng/mL 6.94.0 13.56.4 <0.001
Plasma sCD40L, ng/mL 14.49.0 33.215.6 <0.001
Platelet sP-selectin, ng/mL 10.43.7 14.22.6 <0.001
Platelet sCD40L, ng/mL 1.40.2 4.21.5 <0.001
Platelet sNOx2-dp, pg/mL 5.31.5 13.64.8 <0.001
Platelet 8-iso-PGF2a, pmol/L 45.735.0 79.818.3 <0.001
Platelet NOx, lmol/L 31.719.3 13.18.8 <0.001
BMI indicates body mass index; NOx, NADPH oxidase.
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Table 2. Clinical Characteristics of X-Chronic Granulomatous Disease (X-CGD) Carriers, Controls and Obese Patients
X-CGD Carriers (n=31) P Value* Controls (n=31) P Value* Obese Patients (n=31)
Age, y 41.614.3 1.0 41.214.3 1.0 42.613.7
Gender 31 females n.s. 31 females n.s. 31 females
Systolic blood pressure, mm Hg 1166 1.0 1177 0.05 1205
Diastolic blood pressure, mm Hg 728 1.0 7210 0.573 757
BMI 24.24.3 1.0 24.85.7 0.001 32.54.8
Total-cholesterol, mg/dL 199.879.7 1.0 196.788.7 0.076 244.981.3
Current smokers 11/31 1.0 11/31 1.0 10/31
Hypertension 4/31 1.0 4/31 0.919 5/31
Hypercholesterolemia 0/31 0.472 2/31 0.256 6/31
Type 2 diabetes mellitus 0/31 1.0 1/31 0.351 4/31
Plasma sP-selectin, ng/mL 13.96.8 <0.001 32.06.4 <0.001 54.525.0
Plasma sCD40L, ng/mL 34.510.4 <0.001 57.725.4 <0.001 84.928.0
Platelet sP-selectin, ng/mL 14.06.6 <0.001 23.26.4 <0.001 42.525.0
PlateletsCD40L, ng/mL 3.31.1 <0.001 6.11.7 <0.001 16.02.9
Platelet sNOx2-dp, pg/mL 6.93.5 0.04 13.69.3 <0.001 27.119.3
Platelet 8-iso-PGF2a, pmol/L 62.933.6 <0.001 114.550.2 <0.001 245.350
Platelet NOx, lmol/L 20.77.7 0.04 14.45.5 0.04 7.33.7
Drugs
Statin 0/31 0.472 2/31 0.256 6/31
Angiotensin-converting enzyme inhibitors 4/31 1.0 4/31 1.0 5/31
Corticosteroid therapy 2/31 1.0 1/31 1.0 0/31
Methotrexate 1/31 1.0 1/31 1.0 0/31
Hydroxychloroquine 2/31 0.472 0/31 1.0 0/31
BMI indicates body mass index; NOx, NADPH oxidase.
*Compared with controls.
A B
Figure 1. Plasma sCD40L (A), and plasma sP-selectin (B) levels in adult controls, X-CGD
carriers, obese patients, X-CGD patients and children controls (*P<0.001, **P<0.05).
X-CGD indicates X-linked chronic granulomatous disease.
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P=0.031), BMI (r=0.393, P<0.001), systolic blood pressure
(r=0.210, P=0.01), and diastolic blood pressure (r=0.204,
P=0.01).
Ex Vivo Study
In young subjects, X-CGD disclosed less oxidative stress, as
assessed by platelet sNOx2-dp release and 8-iso-PGF2a
(62% and 43%, respectively, P<0.001), compared with HS
(Table 1 and Figure 2). Furthermore, NO generation, as
assessed by platelet NOx, was signiﬁcantly higher in X-CGD
patients (+140%, P<0.001) compared with young HS (Table 1
and Figure 2).
In adults, platelet sNOx2-dp release and 8-iso-PGF2a were
different among the 3 groups (Table 2 and Figure 3). Thus,
compared with controls, X-CGD carriers had lower levels of
platelet sNOx2-dp (50%, P=0.04) and 8-iso-PGF2a (46%,
P<0.001) (Table 2 and Figure 3). Also, compared with
controls, obese women had higher levels of platelet sNOx2-
dp (+99%, P<0.001) and 8-iso-PGF2a (+114%, P<0.001)
(Table 2 and Figure 3A and 3B). Platelet NOx differed in the 3
groups. Thus, compared with controls, X-CGD carriers and
obese patients had signiﬁcantly higher (+44%, P=0.04) and
lower (50%, P=0.04) levels of platelet NOx, respectively
(Table 2 and Figure 3C).
Compared with young HS, levels of platelet sCD40L and
sP-selectin were reduced in X-CGD patients (67% and 27%,
respectively, P<0.001) (Table 2 and Figure 4). Compared with
adult controls, X-CGD carriers had lower levels of platelet
sCD40L and sP-selectin (40%, P<0.001, and 46%,
P<0.001, respectively) (Table 2 and Figure 4). Also, compared
with controls, obese women had higher levels of platelet
A B
C
Figure 2. Platelet sNOx2-dp release (A), platelet 8-iso-PGF2a formation (B) and platelet
NOx production in X-CGD patients and children controls (*P<0.001, **P<0.05). NOx
indicates NADPH oxidase; X-CGD, X-linked chronic granulomatous disease.
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sCD40L and sP-selectin (+162% and +83%, respectively,
P<0.001).
Discussion
The present study reports the ﬁrst evidence that NOx2 activity
is signiﬁcantly associated with platelet activation in vivo. In
particular, we demonstrated that plasma levels of sCD40L and
sP-selectin were reduced in subjects with X-CGD affected by
complete or partial NOx2 deﬁciency and increased in obese
subjects, who disclosed NOx2 upregulation. Experimental and
clinical studies consistently showed that platelet NOx2 is
implicated in platelet activation. In an experimental model of
platelet-dependent thrombosis, Dayal et al5 demonstrated
that aged animals are characterized by platelet H2O2, which
was associated with higher tendency to thrombosis; such
prothrombotic change was signiﬁcantly impaired by treatment
with apocynin, which inhibits p47phox assembly to NOx2 on
platelet surface.5 The interplay between platelet hyperactivity
and NOx2 was corroborated by the fact that H2O2 overpro-
duction was associated with enhanced levels of mRNA for the
catalytic subunit NOx2 and the cytosolic subunit p47phox.5
Consistent with these ﬁndings, experimental research in
animals demonstrated that apocynin also impairs platelet
function in vivo and that NOx2 activation is therefore
implicated in platelet activation. Thus, a molecular image of
mice prone to atherosclerosis and treated with or without
apocynin demonstrated enhanced platelet adhesion to ath-
erosclerotic plaque in untreated animals, an effect that was
dose-dependently abrogated in animals treated with apocy-
nin.5 That NOx2 is relevant for platelet activation was also
corroborated by investigating platelet activation in patients
with X-CGD, whose platelets disclosed severe but not
A B
C
Figure 3. Platelet sNOx2-dp release (A), platelet 8-iso-PGF2a formation (B) and platelet
NOx production in adult controls, X-CGD carriers, and obese patients (*P<0.001,
**P<0.05). NOx indicates NADPH oxidase; X-CGD, X-linked chronic granulomatous disease.
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complete suppression of platelet O2
 as a consequence of the
hereditary deﬁciency of NOx2 along with impaired ex vivo
aggregation.6 In particular, on activation, platelets from X-
CGD patients disclosed impaired release of CD40L; lowered
formation of isoprostanes, which are chemically stable
eicosanoids with proaggregating property; and reduced
platelet recruitment.6
The impact of NOx2 regulation on markers of in vivo
platelet activation has never been explored. We decided to
investigate in vivo platelet activation in X-CGD patients and
in the X-CGD patients’ mothers, who are carriers of NOx2
deﬁciency. Both represent a unique model of complete or
partial deﬁciency of NOx2 and can give the opportunity to
assess the interplay, if any, between the rate of NOx2 activity
and in vivo platelet activation. To investigate this issue, we
measured 2 biomarkers, namely sCD40L and sP-selectin,
which are established markers of in vivo platelet activation.18
A signiﬁcant reduction in both markers was detected in
X-CGD and NOx2 carriers compared with their respective
controls; however, no difference in the inhibition rate of the 2
biomarkers was detected between X-CGD patients and X-CGD
carriers. This ﬁnding was corroborated by analysis of in vivo
platelet activation in obese subjects who, conversely, dis-
closed NOx2 upregulation coincidentally with a signiﬁcant
increase of both sCD40L and sP-selectin. This is consistent
with previous studies showing upregulation of NOx2 in
patients with atherosclerotic risk factors such as those with
hypercholesterolemia19,20 or diabetes.21
To substantiate these in vivo data, we performed ex vivo
experiments in which the expression of CD40L and P-selectin
was measured in subjects with different degrees of NOx2
regulation. Consistent with in vivo study, platelet expression
of both CD40L and P-selectin was signiﬁcantly reduced in
both X-CGD and NOx2 deﬁciency carriers compared with
the respective controls. Such reduction was coincident with
impaired platelet isoprostane production, which is likely to
reﬂect the reduced formation of ROS in X-CGD and NOx2
deﬁcient carriers and with enhanced platelet NO generation.7
In contrast to these ﬁndings, obese patients disclosed
signiﬁcantly higher expression of platelet CD40L and
P-selectin along with a higher production of platelet isopros-
tanes, further corroborating the concept of a direct interplay
between NOx2 regulation and in vivo platelet activation.
There are at least 2 mechanisms that may potentially
account for NOx2-dependent platelet activation. Thus, ROS
generation by NOx2 rapidly inactivate NO, which is a powerful
antiplatelet molecule.6 On the other hand, ROS generated by
NOx2 may interact with arachidonic acid to give formation of
isoprostanes, which are proaggregating molecules contribut-
ing to propagate platelet aggregation.22 Consistent with this,
NOx2 downregulation was associated with impaired isopros-
tane formation and enhanced NO generation.
As a limitation of the study, we must take into account the
possibility that some antibiotics such as beta-lactams22 may
inhibit platelet activation; however, this potential bias can be
reasonably excluded because inhibition of platelet activation
was also detected in X-GCD carriers, who were not taking
antibiotics.
The study has pharmacologic implications. Thus, the direct
association between NOx2 activity and in vivo platelet
activation suggests that downregulation of NOx2 activation
may represent a novel tool to inhibit platelet activation.
A B
Figure 4. Platelet sCD40L (A), and platelet sP-selectin (B) levels in adult controls, X-CGD
carriers, obese patients, X-CGD patients and children controls (*P<0.001, **P<0.05).
X-CGD indicates X-linked chronic granulomatous disease.
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This potentially interesting new therapeutic option should
be, however, wisely considered as NOx2 has a key role in the
innate immune system and its downregulation could be
associated with a higher risk of infectious disease. Thus, the
extent to which NOx2 may be reduced without interfering with
the activity of innate immune system is a critical issue that
should be taken into account. Some interesting clues on how
developing a drug that inhibits platelet activation without
interfering with the innate immune system are provided by the
present study showing that female carriers of NOx2 hereditary
deﬁciency have lower platelet activation compared with
controls without suffering from bleeding complications or
serious infections.11 This would imply that up to 50% NOx2
activity lowering may be relatively well tolerated without
serious clinical consequence. Inhibition of NOx2 activity
without directly interfering with NOx2 may be another option.
Thus, experimental studies with apocynin, which inhibits
p47phox translocation to membrane NOx2, has been shown
to reduce platelet activation in vivo and in vitro.5,17 However,
apocynin has been studied only in experimental models of
atherosclerosis so far.
Experimental and clinical studies have shown that oxida-
tive stress is implicated in clotting system and platelet
activation; therefore, its inhibition may reduce thrombosis-
related vascular disease.23 However, the results of interven-
tional trials with vitamin E alone and/or in combination with
other antioxidant vitamins provided inconclusive ﬁndings.24
In addition to several factors that may have biased such
results,25 it may be possible that downstream inhibition of
oxidant species, as exerted by antioxidant vitamins, does not
represent an ideal approach to prevent oxidative stress-
related cellular damage. The present study suggests that
upstream inhibition of oxidative stress by targeting precise
cellular oxidant pathways such as NOx2 or other prooxidant
enzymatic pathways may represent an alternative option not
only to inhibit platelet activation but also to retard athero-
sclerotic progression.
In conclusion, we demonstrate that NOx2-derived platelet
ROS formation is implicated in platelet activation ex vivo and
in vivo with a mechanism involving NO and isoprostane
generation. Downregulation of NOx2 activation may represent
a new tool for platelet activation inhibition.
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